Impact of Recombinant Human Erythropoietin Treatment on Left Ventricular Hypertrophy and Cardiac Function in Dialysis Patients

1998 ◽  
Vol 16 (6) ◽  
pp. 317-324 ◽  
Author(s):  
Carlo Massimetti ◽  
Daniele Pontillo ◽  
Sandro Feriozzi ◽  
Stefano Costantini ◽  
Aldo Capezzuto ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Cardiac Function ◽  
Recombinant Human Erythropoietin ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Dialysis Patients ◽  
Human Erythropoietin ◽  
Erythropoietin Treatment

scholarly journals The effect of erythropoietin treatment on left ventricular hypertrophy in haemodialysis patients

2003 ◽  
Vol 3 (4) ◽  
pp. 11-15 ◽  
Author(s):  
Senija Rašić ◽  
Indira Kulenović ◽  
Irfan Zulić ◽  
Azra Haračić ◽  
Mithat Čengić ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Recombinant Human Erythropoietin ◽  
Ventricular Hypertrophy ◽  
Significant Negative Correlation ◽  
Left Ventricular ◽  
Chronic Haemodialysis ◽  
Human Erythropoietin ◽  
Lv Mass ◽  
Erythropoietin Treatment ◽  
Anaemia Correction

Anaemia appears to play an important role in left ventricular (LV) enlargement in chronic kidney disease patients. The objective of this study was to evaluate LV echocardiography changes during anaemia correction with recombinant human erythropoietin(rHu-Epo) in chronic haemodialysis patients (HD pts) with signs of anaemia and LV hypertrophy (LVH). The study included 20 HD pts aged 39,6 +/- 5,3 yrs, with the same condition of HD treatment, anaemia and echocardiographically LVH verified. At the beginning of the rHu-Epo treatment haemoglobin (Hb) level was < 90 g/L and the target Hb level was 110 g/L. Echocardiography was performed at the beginning (baseline) and after six months of rHu-Epo treatment. LVH was defined as LV mass index >100 g/m2 in women and >131 g/m2 in men. We observed significant reduction of LV mass index (LVMI) (mean 26,4%, p=0.008), as well as LV volumen. There was a significant negative correlation between Hb level and LVMI with predictive LVMI reduction of 2,317 g/m2 for each 1g/L rising of mean Hb level. The results of the study confirm the importance of early anaemia correction in haemodialysis patients aimed to improve LV parameters.

scholarly journals Nutrition, anaemia and erythropoietin therapy

1999 ◽  
Vol 3 (2) ◽  
Author(s):  
Iain C. Macdougall
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Ventricular Hypertrophy ◽  
Haemoglobin Concentration ◽  
Left Ventricular ◽  
Dialysis Patients ◽  
Renal Anaemia ◽  
Human Erythropoietin ◽  
Cardiovascular Morbidity And Mortality ◽  
Objective Evidence

During the last decade, recombinant human erythropoietin has revolutionised the management of renal anaemia. It is highly effective in the vast majority of patients treated, causing enhanced erythropoiesis and a rise in haemoglobin concentration. This has resulted not only in amelioration of uraernic symptoms, but there has also been objective evidence of improved quality-of-life, exercise capacity, and cardiac function [I]. The most striking benefits seen have been progression of left ventricular hypertrophy which is known to account for much of the high cardiovascular morbidity and mortality seen in dialysis patients. and thus the arguments for correcting renal anaemia is now overwhelming. There is also an improvement in nutrition following erythropoietin therapy, over and above the improvement in appetite associated with correction of the anaemia.

The Clinical Course of Left Ventricular Hypertrophy in Dialysis Patients

Nephron ◽  
1990 ◽  
Vol 55 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Patrick S. Parfrey ◽  
John D. Harriett ◽  
Sheila M. Griffiths ◽  
Rhoda Taylor ◽  
John D. Harnett ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Clinical Course ◽  
Left Ventricular ◽  
Dialysis Patients

scholarly journals Correlations of circulating miR-26b level with left ventricular hypertrophy and cardiac function in elderly patients with hypertension

2021 ◽  
Vol 37 (4) ◽  
Author(s):  
Jian Fu ◽  
Fang Lin ◽  
Zhengxia Pan ◽  
Chun Wu
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Elderly Patients ◽  
Cardiac Function ◽  
Clinical Data ◽  
Ventricular Hypertrophy ◽  
Protective Factor ◽  
Left Ventricular ◽  
Potential Biomarker ◽  
Biochemical Indices ◽  
Level Group

Objectives: To study the correlations of circulating miR-26b level with left ventricular hypertrophy (LVH) and cardiac function in elderly patients with hypertension. Methods: A total of 132 eligible patients were divided into low and high miR-26b level groups. Their baseline clinical data and biochemical indices were compared. The correlations between miR-26b level and echocardiographic parameters were studied by Pearson’s analysis. Factors affecting LVH were explored by multivariate logistic regression analysis. The role of miR-26b in diagnosing LVH was predicted by receiver operating characteristic curve. Results: The relative expression level of miR-26b was 4.56-16.93, with a median of 7.62. The two groups had similar baseline clinical data and biochemical indices (P>0.05). Compared with high miR-26b level group, interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular mass index (LVMI) and number of LVH cases in low miR-26b level group significantly increased (P<0.05), and mitral ratio of peak early to late diastolic filling velocity (E/A) decreased (P<0.05). Circulating miR-26b level was negatively correlated with IVST, LVPWT and LVMI (P<0.0001), and positively correlated with E/A (P<0.0001). The proportion of cardiac hypofunction cases in low miR-26b level group significantly exceeded that of high miR-26b level group (P<0.05). Age and increased IVST, LVPWT and LVMI were independent risk factors for LVH (P<0.05), and elevated miR-26b level was a protective factor (P<0.05). AUC was 0.836, and the optimal cutoff value was 8.83, with high sensitivity and specificity. Conclusions: MiR-26b level is negatively correlated with LVH and positively correlated with left ventricular diastolic function in elderly hypertensive patients. It is a protective factor for LVH complicated with diastolic dysfunction and a potential biomarker for diagnosis. doi: https://doi.org/10.12669/pjms.37.4.4048 How to cite this:Fu J, Lin F, Pan Z, Wu C. Correlations of circulating miR-26b level with left ventricular hypertrophy and cardiac function in elderly patients with hypertension. Pak J Med Sci. 2021;37(4):---------. doi: https://doi.org/10.12669/pjms.37.4.4048 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sex Difference in the Prevalence of Left Ventricular Hypertrophy in Dialysis Patients

2008 ◽  
Vol 29 (5) ◽  
pp. 398-405 ◽  
Author(s):  
Li-Tao Cheng ◽  
Yan-Li Gao ◽  
Jun-Ping Tian ◽  
Yue Gu ◽  
Li Zhang ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Sex Difference ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Dialysis Patients
Sign in / Sign up

Export Citation Format

Share Document